Last reviewed · How we verify
Magnesium Pantoprazole
Magnesium pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion.
Magnesium pantoprazole inhibits the proton pump in gastric parietal cells, reducing gastric acid secretion. Used for Gastroesophageal reflux disease (GERD), Peptic ulcer disease, Acid-related gastrointestinal disorders.
At a glance
| Generic name | Magnesium Pantoprazole |
|---|---|
| Sponsor | Takeda |
| Drug class | Proton pump inhibitor (PPI) |
| Target | H+/K+-ATPase (proton pump) |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | Phase 3 |
Mechanism of action
Pantoprazole is a proton pump inhibitor (PPI) that irreversibly binds to and blocks the H+/K+-ATPase enzyme in the gastric mucosa, preventing the final step of gastric acid production. The magnesium salt formulation improves bioavailability and gastrointestinal tolerability compared to standard pantoprazole formulations. This mechanism provides sustained acid suppression for the treatment of acid-related gastrointestinal disorders.
Approved indications
- Gastroesophageal reflux disease (GERD)
- Peptic ulcer disease
- Acid-related gastrointestinal disorders
Common side effects
- Headache
- Diarrhea
- Nausea
- Abdominal pain
- Hypomagnesemia (with long-term use)
Key clinical trials
- Prophylactic Proton Pump Inhibition for Esophageal Protection in Lung Radiation Therapy (PHASE2)
- Opioid Therapy vs Multimodal Analgesia in Head and Neck Cancer (PHASE2)
- A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD) (PHASE2)
- A Trial of IW-3718 for 8 Weeks in Patients With Symptomatic Gastroesophageal Reflux Disease (GERD) (PHASE2)
- Symptomatic Relief of Acute Dyspeptic Pain in Emergency Department With Pantoprazole (PHASE4)
- Magnesium Pantoprazole 20mg b.i.d. vs Magnesium Pantoprazole 40mg q.d. on Intragastric Acid Inhibition (PHASE3)
- Pantoprazole Magnesium 40 mg Versus Esomeprazole 40 mg in Patients With Erosive Gastroesophageal Reflux Disease (PHASE3)
- Comparison of a "Step-Up" Versus a "Step-Down" Treatment Strategy for Patients With New Onset Dyspepsia in General Practice (The DIAMOND-Study) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |